Galectin Therapeutics (GALT) Prepaid Assets (2010 - 2026)
Galectin Therapeutics (GALT) posted quarterly Prepaid Assets of $1.6 million for Q1 2026, down 14.78% year-over-year from $1.9 million in Q1 2025, and down 7.93% quarter-over-quarter from $1.7 million in Q4 2025.
Analysis
Galectin Therapeutics (GALT) Prepaid Assets (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Prepaid Assets history runs 17 years deep, the most recent figure standing at $1.6 million for Q1 2026.
- In Q1 2026, Prepaid Assets fell 14.78% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $1.6 million (down 14.78% YoY), while the FY2025 annual figure was $1.7 million, down 19.51% from the prior year.
- Prepaid Assets for Q1 2026 stood at $1.6 million, down from $1.7 million in the prior quarter.
- The five-year high for Prepaid Assets was $2.1 million in Q4 2024, with the low at $1.2 million in Q3 2025.
- The 5-year median for Prepaid Assets is $1.7 million (2024), against an average of $1.7 million.
- The sharpest annual moves came in 2024 and 2025: Prepaid Assets gained 28.58% in 2024, then slipped 25.03% in 2025.
- Galectin Therapeutics' Prepaid Assets stood at $2.0 million in 2022, then climbed by 4.59% to $2.0 million in 2023, then advanced by 4.0% to $2.1 million in 2024, then fell by 19.51% to $1.7 million in 2025, then slipped by 7.93% to $1.6 million in 2026.
- Business Quant data shows GALT's Prepaid Assets at $1.6 million in Q1 2026, $1.7 million in Q4 2025, and $1.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Galectin Therapeutics | 304.34 Mn | 304.34 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.39 Mn |
| Mar 31, 2026 | 1.58 Mn |
| Dec 31, 2025 | 1.72 Mn |
| Sep 30, 2025 | 1.20 Mn |
| Jun 30, 2025 | 1.66 Mn |
| Mar 31, 2025 | 1.85 Mn |
| Dec 31, 2024 | 2.13 Mn |
| Sep 30, 2024 | 1.61 Mn |
| Jun 30, 2024 | 1.69 Mn |
| Mar 31, 2024 | 1.91 Mn |
| Dec 31, 2023 | 2.05 Mn |
| Sep 30, 2023 | 1.25 Mn |
| Jun 30, 2023 | 1.50 Mn |
| Mar 31, 2023 | 1.75 Mn |
| Dec 31, 2022 | 1.96 Mn |
| Sep 30, 2022 | 1.29 Mn |
| Jun 30, 2022 | 1.61 Mn |
| Mar 31, 2022 | 1.90 Mn |
| Dec 31, 2021 | 2.17 Mn |
| Sep 30, 2021 | 1.40 Mn |